Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine
- 1 April 1978
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 92 (4), 648-652
- https://doi.org/10.1016/s0022-3476(78)80315-1
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron OverloadNew England Journal of Medicine, 1977
- SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOADThe Lancet, 1976
- Antipyrine clearance in homozygous β‐thalassemiaClinical Pharmacology & Therapeutics, 1976
- Reassessment of the Use of Desferrioxamine B in Iron OverloadNew England Journal of Medicine, 1976
- HEME CONTROL ON THE SYNTHESIS OF DELTA‐AMINOLEVULINIC ACID SYNTHETASE IN CULTURED CHICK EMBRYO LIVER CELLS*Annals of the New York Academy of Sciences, 1975
- Drug metabolism in normal children, lead‐poisoned children, and normal adultsClinical Pharmacology & Therapeutics, 1975
- Serum ferritin in children with thalassaemia regularly transfusedJournal of Clinical Pathology, 1974
- Clinical and Laboratory Studies on the Action of DesferrioxamineBritish Journal of Haematology, 1969
- Deferoxamine mesylate (Desferal mesylate); A specific iron‐chelating agent for treating acute iron intoxicationClinical Pharmacology & Therapeutics, 1969
- Iron chelation in haematomas at fracture sitesJournal of Clinical Pathology, 1966